Advertisement
John Nicholson, Chairman and CEO of Gentronix, comments, "We are delightedto complete this agreement with BioReliance, a company regarded as a globalleader in genetic toxicology testing services." "This new high-throughputassay from Gentronix furthers BioReliance's ability to meet customer demandfor faster and more effective genotoxic screening services," adds DavidBruning, Senior Director, Toxicology Operations at BioReliance. "TheGreenScreen HC and Ames II assays, when combined, offer highly predictive andsensitive detection of genotoxic compounds while minimizing false positivesseen with other in vitro assays, accelerating the development process."
Advertisement
GreenScreen HC is a unique human cell-based genotoxicity screening assaythat links the regulation of the human Growth Arrest and DNA Damage (GADD45a)gene to the production of Green Fluorescent Protein (GFP). Cells that haveincurred DNA damage upon exposure to a test compound express higher levels ofdetectable GFP.
GreenScreen HC only requires 1 mg of starting material to demonstrate highspecificity, in contrast to other in vitro genetic toxicology assays thatoften provide false positive results. GreenScreen HC is able to detectmultiple mechanistic classes of genotoxic agents, including aneugens, and iseasily adapted to automatic robotic platforms.
About Gentronix
Gentronix is an innovative biotechnology company helping to accelerate thepace of drug development in the pharmaceutical industry. Gentronix isdeveloping a range of productivity-enhancing tools for scientists in the drugdiscovery field, designed to ease or remove current bottlenecks in preclinicalresearch and development. Gentronix's first product release, GreenScreen,successfully combines expertise in molecular biology and analytical science toaddress the ADMET bottleneck in lead candidate selection, focusingspecifically on genotoxicity screening. GreenScreen products are for use ingenetic toxicity screening and can contribute to the selection of leadcollections enriched with compounds lacking genotoxicity. For moreinformation, visit www.gentronix.co.uk .
About BioReliance
BioReliance Corporation is a leading contract services organization,offering more than 1,000 tests or services related to biologics safetytesting, in vitro and in vivo toxicology, viral manufacturing and lab animalhealth diagnostics for the biopharmaceutical and pharmaceutical industries.The Company provides cost-effective services to over 600 clients annually,including most of the largest pharmaceutical and biopharmaceutical companiesin the world. BioReliance is headquartered in Rockville, Maryland and hasadditional facilities in Glasgow, Scotland and Stirling, Scotland. For moreinformation, visit www.bioreliance.com .Contact Peter McCulloch Director, Business Development [email protected] +44 161 606 7268
SOURCE BioReliance Corporation
